Clinical utility of PET/CT in malignant pleural mesothelioma

http://www.ncbi.nlm.nih.gov/pubmed/23139709

Exp Ther Med. 2012 Aug;4(2):197-200. Epub 2012 May 11.

Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma.

Terada T, Tabata C, Tabata R, Okuwa H, Kanemura S, Shibata E, Nakano T.

Source

Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine ; Department of Thoracic Oncology, Hyogo College of Medicine.

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure. MPM has a limited response to conventional chemotherapy and radiotherapy, thus early diagnosis of MPM is extremely critical. CT scans have limited accuracy in the differentiation between benign and malignant pleural disease. Several studies have reported that 18-fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the assessment of thoracic malignancy such as lung cancer. Here, we investigated the clinical utility of PET in patients with MPM. The maximum SUV (SUVmax) of 18F-FDG was measured in 47 MPM patients and 29 non-MPM patients including those with pleural thickening. We demonstrated that patients with MPM had significantly higher SUVmax levels than a population with non-malignant pleural disease. The Kaplan-Meier method revealed significant differences in overall survival between groups with SUVmax levels lower and higher than the assumed cut-off. Our data suggest that SUVmax levels are useful as an aid for diagnosis and prognosis of MPM.